Abstract
Abstract
CD133 and CD44 are widely expressed cell-surface markers in glioblastoma multiforme (GBM) and meningiomas respectively. Recent molecular studies revealed that CD133-positive GBM cells have cancer stem cell features with self-renewal and self-recapulating capacity. Similarly, it is also known that CD44 is expressed differentially on various meningioma subtypes and several studies in the literature reported that CD44 expression is correlated with the invasiveness of meningiomas. In this context, we aimed to highlight the expression patterns of CD133 and CD44 and their implications with the potential cancer stem cells in glioblastoma multiforme (GBM) and meningiomas, respectively.
Keywords: Glioma, meningioma, cancer stem cell, CD133, CD44
Özet
CD133 ve CD44 sırasıyla glioblastoma multiforme (GBM) ve meningiomlarda geniş ölçüde tespit edilen hücre yüzey işaret molekülleridir. Yakın zamandaki moleküler çalışmalar CD133 müsbet GBM hücrelerinin kanser kök hücrelerinin sahip olduğu düşünülen ‘kendini yenileme ve yineleme’ özelliklerine sahip olduklarını göstermiştir. Benzer şekilde, CD44 yüzey işaretinin de değişik meningioma alttiplerinde olduğu bilinmektedir ve birkaç çalışmada CD44 miktarıyla meningioma invazyonu arasında ilişki olduğu bildirilmiştir. Bu bağlamda, CD133 ve CD44 hücre yüzey işaret moleküllerinin sırasıyla GBM ve meningiomlardaki sunulma biçimlerini ve bu moleküllerin potansiyel kanser kök hücreleriyle olan ilişkilerini vurgulamayı amaçladık.
Anahtar sözcükler: Gliom, meningiom, kanser kök hücresi, CD133, CD44Keywords
References
- Mizrak D, Brittan M, Alison MR. CD133: molecule of the moment. J Pathol 2008; 214: 3-9.
- Singh SK, Clarke ID, Hide T, Dirks PB. Cancer stem cells in nervous system tumors. Oncogene 2004 23:7267-73.
- Altaner C. Glioblastoma and stem cells. Neoplasma 2008; 55: 369-74.
- Hentschel SJ, Lang FF. Current surgical management of glioblastoma. Cancer J 2003; 9: 113-25.
- Suzuki SO, Iwaki T, Kitamoto T, Mizoguchi M, Fukui M, Tateishi J. Differential expression of CD44 variants among meningioma subtypes. Clin Mol Pathol 1996; 49: 140-6.
- Jagannathan J, Prevedello DM, Dumont AS, Laws ER. Cellular signaling molecules as therapeutic targets in glioblastoma multiforme. Neurosurg Focus 2006; 20: E8.
- Chamberlain MC. Treatment options for glioblastoma. Neurosurg Focus 2006; 20: E19.
- Modha A, Gutin PH. Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery 2005; 57: 538-50.
- Perry A, Gutmann DH, Reifenberger G. Molecular pathogenesis of meningiomas. J Neurooncol 2004; 70: 183-202.
- Carvalho LH, Smirnov I, Baia GS, Modrusan Z, Smith JS, Jun P, Costello JF, McDermott MW, Vandenberg SR, Lal A. Molecular signatures define two main classes of meningiomas. Mol Cancer 2007; 6: 64.
- Dirks PB. Cancer: stem cells and brain tumours. Nature 2006; 444: 687-8.
- Rooprai HK, Liyanage K, King A, Davies D, Martin K, Pilkington GJ. CD44 expression immunohistochemical and flow cytometric analysis. Int J Oncol 1999; 14: 855- 60. meningiomas: An immunocytochemical,
- Resnick DK, Resnick NM, Welch WC, Cooper DL. Differential expressions of CD44 variants in tumors affecting the central nervous system. Mol Diagn 1999; 4: 219-32.
- Joo KM, Kim SY, Jin X, Song SY, Kong DS, Lee JI, Jeon JW, Kim MH, Kang BG, Jung Y, Jin J, Hong SC, Park WY, Lee DS, Kim H, Nam DH. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest 2008; 88: 808-15.
- Sainio M, Zhao F, Heiska L, Turunen O, den Bakker M, Zwarthoff E, Lutchman M, Rouleau GA, Jääskeläinen J, Vaheri A, Carpén O. Neurofibromatosis 2 tumor suppressor protein colocalizes with ezrin and CD44 and associates with actin- containing cytoskeleton. J Cell Sci 1997; 110: 2249-60.
- Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, Gutmann DH, Ponta H, Herrlich P. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 2001 15:968-80.
- McClatchey AI, Giovannini M. Membrane organization and tumorigenesis-the NF2 tumor suppressor, Merlin. Genes Dev 2005; 19: 2265-77.
- Herrlich P, Morrison H, Sleeman J, Orian-Rousseau V, König H, Weg-Remers S, Ponta H. CD44 acts both as a growth-and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann N Y Acad Sci. 2000; 910: 106-18.
- Giovannini M, Robanus-Maandag E, van der Valk M, Niwa-Kawakita M, Abramowski V, Goutebroze L, Woodruff JM, Berns A, Thomas G. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev 2000; 14: 1617-30.
- Kalamarides M, Niwa-Kawakita M, Leblois H, Abramowski V, Perricaudet M, Janin A, Thomas G, Gutmann DH, Giovannini M. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 2002; 16: 1060-5.
Abstract
CD133 ve CD44 sırasıyla glioblastoma multiforme (GBM) ve meningiomlarda geniş ölçüde tespit edilen hücre yüzey işaret molekülleridir. Yakın zamandaki moleküler çalışmalar CD133 müspet GBM hücrelerinin kanser kök hücrelerinin sahip olduğu düşünülen „kendini yenileme ve yineleme‟ özelliklerine sahip olduklarını göstermiştir. Benzer şekilde, CD44 yüzey işaretinin de değişik meningioma alttiplerinde olduğu bilinmektedir ve birkaç çalışmada CD44 miktarıyla meningioma invazyonu arasında ilişki olduğu bildirilmiştir. Bu bağlamda, CD133 ve CD44 hücre yüzey işaret moleküllerinin sırasıyla GBM ve meningiomlardaki sunulma biçimlerini ve bu moleküllerin potansiyel kanser kök hücreleriyle olan ilişkilerini vurgulamayı amaçladık
Keywords
References
- Mizrak D, Brittan M, Alison MR. CD133: molecule of the moment. J Pathol 2008; 214: 3-9.
- Singh SK, Clarke ID, Hide T, Dirks PB. Cancer stem cells in nervous system tumors. Oncogene 2004 23:7267-73.
- Altaner C. Glioblastoma and stem cells. Neoplasma 2008; 55: 369-74.
- Hentschel SJ, Lang FF. Current surgical management of glioblastoma. Cancer J 2003; 9: 113-25.
- Suzuki SO, Iwaki T, Kitamoto T, Mizoguchi M, Fukui M, Tateishi J. Differential expression of CD44 variants among meningioma subtypes. Clin Mol Pathol 1996; 49: 140-6.
- Jagannathan J, Prevedello DM, Dumont AS, Laws ER. Cellular signaling molecules as therapeutic targets in glioblastoma multiforme. Neurosurg Focus 2006; 20: E8.
- Chamberlain MC. Treatment options for glioblastoma. Neurosurg Focus 2006; 20: E19.
- Modha A, Gutin PH. Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery 2005; 57: 538-50.
- Perry A, Gutmann DH, Reifenberger G. Molecular pathogenesis of meningiomas. J Neurooncol 2004; 70: 183-202.
- Carvalho LH, Smirnov I, Baia GS, Modrusan Z, Smith JS, Jun P, Costello JF, McDermott MW, Vandenberg SR, Lal A. Molecular signatures define two main classes of meningiomas. Mol Cancer 2007; 6: 64.
- Dirks PB. Cancer: stem cells and brain tumours. Nature 2006; 444: 687-8.
- Rooprai HK, Liyanage K, King A, Davies D, Martin K, Pilkington GJ. CD44 expression immunohistochemical and flow cytometric analysis. Int J Oncol 1999; 14: 855- 60. meningiomas: An immunocytochemical,
- Resnick DK, Resnick NM, Welch WC, Cooper DL. Differential expressions of CD44 variants in tumors affecting the central nervous system. Mol Diagn 1999; 4: 219-32.
- Joo KM, Kim SY, Jin X, Song SY, Kong DS, Lee JI, Jeon JW, Kim MH, Kang BG, Jung Y, Jin J, Hong SC, Park WY, Lee DS, Kim H, Nam DH. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest 2008; 88: 808-15.
- Sainio M, Zhao F, Heiska L, Turunen O, den Bakker M, Zwarthoff E, Lutchman M, Rouleau GA, Jääskeläinen J, Vaheri A, Carpén O. Neurofibromatosis 2 tumor suppressor protein colocalizes with ezrin and CD44 and associates with actin- containing cytoskeleton. J Cell Sci 1997; 110: 2249-60.
- Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, Gutmann DH, Ponta H, Herrlich P. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 2001 15:968-80.
- McClatchey AI, Giovannini M. Membrane organization and tumorigenesis-the NF2 tumor suppressor, Merlin. Genes Dev 2005; 19: 2265-77.
- Herrlich P, Morrison H, Sleeman J, Orian-Rousseau V, König H, Weg-Remers S, Ponta H. CD44 acts both as a growth-and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann N Y Acad Sci. 2000; 910: 106-18.
- Giovannini M, Robanus-Maandag E, van der Valk M, Niwa-Kawakita M, Abramowski V, Goutebroze L, Woodruff JM, Berns A, Thomas G. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev 2000; 14: 1617-30.
- Kalamarides M, Niwa-Kawakita M, Leblois H, Abramowski V, Perricaudet M, Janin A, Thomas G, Gutmann DH, Giovannini M. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 2002; 16: 1060-5.
Details
| Primary Language | English |
|---|---|
| Journal Section | Reviews |
| Authors | |
| Publication Date | June 20, 2011 |
| Published in Issue | Year 2011Volume: 33 Issue: 2 |